38 related articles for article (PubMed ID: 26463827)
1. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma.
Duckett ME; Curran KM; Bracha S; Leeper HJ
J Am Anim Hosp Assoc; 2024 Jan; 60(1):7-14. PubMed ID: 38175982
[TBL] [Abstract][Full Text] [Related]
2. Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.
Fournier Q; Serra JC; Handel I; Lawrence J
J Vet Intern Med; 2018 Jan; 32(1):384-393. PubMed ID: 29205493
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical response and prognostic factors in canine multicentric lymphoma treated with first rescue therapy.
Blaxill JE; Bennett PF
Vet Comp Oncol; 2024 Jun; 22(2):265-277. PubMed ID: 38646859
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of factors influencing survival time in 77 dogs with lymphoma.
Jeong SY
Open Vet J; 2023 Sep; 13(9):1124-1134. PubMed ID: 37842100
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
[TBL] [Abstract][Full Text] [Related]
6. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma.
Sztukowski KE; Yaufman Z; Cook MR; Aarnes TK; Husbands BD
J Vet Intern Med; 2024; 38(3):1686-1692. PubMed ID: 38563346
[TBL] [Abstract][Full Text] [Related]
7. Novel Treatments for Lymphoma.
Thamm DH
Vet Clin North Am Small Anim Pract; 2024 May; 54(3):477-490. PubMed ID: 38199913
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of carboplatin in the treatment of macroscopic mesenchymal neoplasia in dogs.
Pritchard C; Al-Nadaf S; Rebhun RB; Willcox JL; Skorupski KA; Lejeune A
Vet Comp Oncol; 2023 Dec; 21(4):717-725. PubMed ID: 37705417
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of chemotherapeutic effect without wide-margin surgery or radiation therapy in dogs with oral malignant melanoma.
Xia Y; Liao AT; Lee J
Can Vet J; 2024 Apr; 65(4):343-350. PubMed ID: 38562982
[TBL] [Abstract][Full Text] [Related]
10. Comparison of chemotherapy outcomes between normal and high serum cortisol concentration in dogs with lymphoma.
Yamazaki H; Bunbai K; Deguchi T; Tamura M; Ohota H
J Vet Intern Med; 2024; 38(3):1651-1658. PubMed ID: 38471970
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of carboplatin sustained-release delivery system in dogs with cancer.
Tansey Baldwin C; Zwahlen CH; Kirschner S; Nakamura RK
Vet Med Sci; 2016 Aug; 2(3):147-153. PubMed ID: 29067189
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs.
Silva LP; Yamamoto PA; Machado MCA; Neves FMF; Azeredo FJ; Dos Santos Silva ACS; Hlavac N; de Melo Soares D; Godoy ALPC; Estrela-Lima A
Res Vet Sci; 2023 Mar; 156():14-21. PubMed ID: 36738520
[TBL] [Abstract][Full Text] [Related]
13. Review of Canine Lymphoma Treated with Chemotherapy-Outcomes and Prognostic Factors.
Bennett P; Williamson P; Taylor R
Vet Sci; 2023 May; 10(5):. PubMed ID: 37235425
[TBL] [Abstract][Full Text] [Related]
14. Interaction of Lipophilic Cytarabine Derivatives with Biomembrane Model at the Air/Water Interface.
Berrio Escobar JF; Giordani C; Russo S; Castelli F; Sarpietro MG
Membranes (Basel); 2022 Sep; 12(10):. PubMed ID: 36295696
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Gillem J; Giuffrida M; Krick E
Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
18. Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma.
Batschinski K; Dervisis N; Kitchell B; Newman R; Erfourth T
J Am Anim Hosp Assoc; 2018; 54(3):150-155. PubMed ID: 29558212
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
